Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide Positron emission tomography (PET) using radioligands for the enzyme monoamine oxidase B (MAO-B) is increasingly applied as a marker for astrogliosis in neurodegenerative disorders. In the present study, a novel reversible fluorine-18 labeled MAO-B compound, [ 18 F]GEH200449, was evaluated as a PET radioligand in non-human primates. PET studies of [ 18 F]GEH200449 at baseline showed brain exposure (maximum concentration: 3.4–5.2 SUV; n = 5) within the range of that for suitable central nervous system radioligands and a regional distribution consistent with the known localization of MAO-B. Based on the quantitative assessment of [ 18 F]GEH200449 data using the metabolite-corrected arterial plasma concentration as input function, the Logan graphical analysis was selected as the preferred method of quantification. The binding of [ 18 F]GEH200449, as calculated based on regional estimates of the total distribution volume, was markedly inhibited (occupancy >80%) by the administration of the selective MAO-B ligands L -deprenyl (0.5 and 1.0 mg/kg) or rasagiline (0.75 mg/kg) prior to radioligand injection. Radioligand binding was displaceable by the administration of L -deprenyl (0.5 mg/kg) at 25 min after radioligand injection, thus supporting reversible binding to MAO-B. These observations support that [ 18 F]GEH200449 is a reversible MAO-B radioligand suitable for applied studies in humans.
No takes yet. Share an insight, caveat, or question.
Varnäs et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: